ML-007 is a selective muscarinic acetylcholine M<sub>1</sub> and M<sub>4</sub> receptor agonist which is under development for the treatment of schizophrenia, psychotic disorders, and dyskinesias. It is being developed in combination with a peripherally selective muscarinic acetylcholine receptor antagonist (also known as ML-007/peripherally acting anticholinergic or ML-007/PAC). The drug is taken by mouth.
As of January 2024, ML-007 is in phase 1 clinical trials for schizophrenia, psychotic disorders, and dyskinesias. It is under development by MapLight Therapeutics. The drug is a small molecule, but its chemical structure does not seem to have been disclosed.